Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
144.8 ^USD	+1.92%		+2.35%	+14.99%

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on September 29, 2021.

November 10, 2021 at 04:12 pm EST

From September 29, 2021 to November 10, 2021, the company has repurchased 154,837 shares, representing 0.29% for $25 million. With this, the company has completed the repurchase of 154,837 shares, representing 0.29% for $25 million under the buyback announced on September 29, 2021.

Latest news about Ascendis Pharma A/S

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	Feb. 29	CI
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	Feb. 16	MT
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	Feb. 09	MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating	Feb. 08	MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating	Feb. 08	MT
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	Feb. 07	MT
Transcript : Ascendis Pharma A/S, 2023 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ASND) ASCENDIS PHARMA Posts Q4 Revenue EUR137.7M	Feb. 07	MT
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07	CI
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07	CI
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating	Feb. 06	MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	Feb. 01	MT
Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31	CI
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading	Jan. 30	MT
Ascendis Spinning Off Ophthalmology Assets into Eyconis with Venture Firms Backing	Jan. 29	MT
European Equities Traded in the US as American Depositary Receipts Jump in Wednesday Trading	Jan. 24	MT
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey	Jan. 08	CI

Chart Ascendis Pharma A/S

Duration

Period

More charts

Company Profile

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ascendis Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

135.4 EUR

Average target price

166.7 EUR

Spread / Average Target

+23.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASCENDIS PHARMA A/S	+14.99%	8.27B
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.11%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.40%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs